PROK
VENTE TOTALE: 81 929 titres (~115 538,52 $ US)
- Insiders
- Pereira Brian JG
- Total bought
- —
- Total sold
- $115,539
- Last activity
- 2026-08-20
- Last synced
-
2026-08-26 03:23:35
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-21
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -16931.0% | -215689.5% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -16194.7% | -208542.1% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -18477.8% | -241678.9% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -16931.5% | -215701.3% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -16977.8% | -214914.5% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -7725.2% | -80507.9% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -7725.2% | -80507.9% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 9.130 | 10.931 | 14.943 | 46.419 | 2.215 | |
| Quick Ratio | 9.130 | 10.931 | 14.943 | 46.419 | 2.215 | |
| Solvency Ratio | -1.794 | -1.414 | -1.082 | -8.041 | -3.973 | |
| Cash Ratio | 3.531 | 2.737 | 2.422 | 45.089 | 1.669 | |
| Price To Earnings Ratio | -4.308 | -2.726 | -3.123 | -3.898 | -5.723 | |
| Price To Earnings Growth Ratio | 0.267 | -0.311 | 0.046 | -2.248 | -0.005 | |
| Forward Price To Earnings Growth Ratio | 0.267 | -0.311 | 0.046 | -2.248 | -0.005 | |
| Price To Earnings Diluted Ratio | -4.308 | -2.726 | -3.123 | -3.898 | -5.723 | |
| Price To Earnings Diluted Growth Ratio | 0.267 | -0.311 | 0.046 | -2.248 | -0.005 | |
| Price To Book Ratio | -0.297 | -0.166 | -0.100 | -0.385 | 11.729 | |
| Price To Sales Ratio | 335.982 | 2,177.347 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -2.217 | -1.062 | -0.884 | -5.348 | -5.689 | |
| Price To Operating Cash Flow Ratio | -2.498 | -1.310 | -1.220 | -5.476 | -6.277 | |
| Debt To Assets Ratio | 0.012 | 0.007 | 0.010 | 0.005 | 0.033 | |
| Debt To Equity Ratio | -0.004 | -0.003 | -0.004 | -0.002 | 0.050 | |
| Debt To Capital Ratio | -0.004 | -0.003 | -0.004 | -0.002 | 0.047 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | -0.332 | -0.443 | -0.381 | -0.472 | 1.497 | |
| Working Capital Turnover Ratio | 0.003 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.907 | -3.489 | -3.597 | -7.090 | -4.085 | |
| Operating Cash Flow Sales Ratio | -134.510 | -1,662.513 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.127 | 1.234 | 1.380 | 1.024 | 1.103 | |
| Debt Service Coverage Ratio | -36,258.250 | -17,543.778 | -10,965.167 | -673.879 | 0.000 | |
| Interest Coverage Ratio | -41,251.750 | -20,408.444 | -12,626.833 | -711.660 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -29.761 | -39.045 | -20.410 | -32.134 | -37.705 | |
| Capital Expenditure Coverage Ratio | -7.905 | -4.282 | -2.634 | -41.760 | -9.688 | |
| Dividend Paid And Capex Coverage Ratio | -7.905 | -4.282 | -2.634 | -41.760 | -9.688 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.986 | -1.764 | -1.537 | -3.266 | -13.125 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | ▲60.0% |
| Ebit Margin | -16931.0% | ▲198758.4% | ▲29593.1% |
| Ebitda Margin | -16194.7% | ▲192347.4% | ▲28752.6% |
| Operating Profit Margin | -18477.8% | ▲223201.1% | ▲33553.5% |
| Pretax Profit Margin | -16931.5% | ▲198769.9% | ▲29595.1% |
| Continuous Operations Profit Margin | -16977.8% | ▲197936.7% | ▲29400.6% |
| Net Profit Margin | -7725.2% | ▲72782.7% | ▲9921.4% |
| Bottom Line Profit Margin | -7725.2% | ▲72782.7% | ▲9921.4% |
| Current Ratio | 9.130 | ▼-1.801 | ▼-7.598 |
| Quick Ratio | 9.130 | ▼-1.801 | ▼-7.598 |
| Solvency Ratio | -1.794 | ▼-0.381 | ▲1.466 |
| Cash Ratio | 3.531 | ▲0.794 | ▼-7.559 |
| Price To Earnings Ratio | -4.308 | ▼-1.582 | ▼-0.352 |
| Price To Earnings Growth Ratio | 0.267 | ▲0.578 | ▲0.717 |
| Forward Price To Earnings Growth Ratio | 0.267 | ▲0.578 | ▲0.717 |
| Price To Earnings Diluted Ratio | -4.308 | ▼-1.582 | ▼-0.352 |
| Price To Earnings Diluted Growth Ratio | 0.267 | ▲0.578 | ▲0.717 |
| Price To Book Ratio | -0.297 | ▼-0.130 | ▼-2.453 |
| Price To Sales Ratio | 335.982 | ▼-1841.365 | ▼-166.684 |
| Price To Free Cash Flow Ratio | -2.217 | ▼-1.156 | ▲0.823 |
| Price To Operating Cash Flow Ratio | -2.498 | ▼-1.188 | ▲0.858 |
| Debt To Assets Ratio | 0.012 | ▲0.005 | ▼-0.002 |
| Debt To Equity Ratio | -0.004 | ▼-0.001 | ▼-0.011 |
| Debt To Capital Ratio | -0.004 | ▼-0.001 | ▼-0.011 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | -0.332 | ▲0.112 | ▼-0.305 |
| Working Capital Turnover Ratio | 0.003 | ▲0.003 | ▲0.002 |
| Operating Cash Flow Ratio | -3.907 | ▼-0.418 | ▲0.526 |
| Operating Cash Flow Sales Ratio | -134.510 | ▲1528.004 | ▲224.895 |
| Free Cash Flow Operating Cash Flow Ratio | 1.127 | ▼-0.107 | ▼-0.047 |
| Debt Service Coverage Ratio | -36258.250 | ▼-18714.472 | ▼-23170.035 |
| Interest Coverage Ratio | -41251.750 | ▼-20843.306 | ▼-26252.012 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -29.761 | ▲9.284 | ▲2.050 |
| Capital Expenditure Coverage Ratio | -7.904 | ▼-3.623 | ▲5.349 |
| Dividend Paid And Capex Coverage Ratio | -7.904 | ▼-3.623 | ▲5.349 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.986 | ▼-2.221 | ▲0.750 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $680.9M | $375.5M | $249.3M | $958.1M | $716.5M | |
| Enterprise value | $576.4M | $279.7M | $193.1M | $470.2M | $697.3M | |
| EV / Sales | 645.47x | 3679.70x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.80x | -2.21x | -2.14x | -6.10x | -13.86x | |
| EV / Free cash flow | -4.26x | -1.79x | -1.55x | -5.96x | -12.56x | |
| EV / EBITDA | -3.99x | -1.76x | -1.54x | -3.27x | -13.12x | |
| Net debt / EBITDA | 0.72x | 0.60x | 0.45x | 3.39x | 0.36x | |
| Current ratio | 9.13x | 10.93x | 14.94x | 46.42x | 2.21x | |
| Income quality | 0.79x | 0.77x | 0.67x | 0.52x | 0.91x | |
| Graham net-net | $2 | $3 | $5 | $8 | $0 | |
| Tax burden | 45.6% | 37.3% | 27.4% | 73.4% | 100.1% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.1% | 100.0% | |
| Working capital | $249.9M | $359.7M | $349.1M | $493.8M | $15.0M | |
| Invested capital | $304.8M | $404.9M | $395.5M | $507.1M | $28.0M | |
| Return on assets | -20.6% | -13.9% | -8.4% | -20.9% | -136.8% | |
| Operating ROA | -42.5% | -42.6% | -32.3% | -54.8% | -193.4% | |
| Return on tangible assets | -20.6% | -13.9% | -8.4% | -20.9% | -138.3% | |
| Return on equity | 6.8% | 6.1% | 3.2% | 9.9% | -204.9% | |
| Return on invested capital | -53.9% | -45.1% | -38.2% | -30.1% | -195.1% | |
| Return on capital employed | -54.1% | -45.4% | -38.3% | -30.2% | -196.9% | |
| Earnings yield | -23.0% | -37.0% | -32.3% | -25.6% | -17.5% | |
| Free cash flow yield | -45.1% | -94.2% | -113.1% | -18.7% | -17.6% | |
| Capex / Op. cash flow | -12.7% | -23.4% | -38.0% | -2.4% | -10.3% | |
| Capex / Depreciation | 231.1% | 543.2% | 887.5% | 60.8% | 261.7% | |
| Capex / Sales | 1701.7% | 38827.6% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 5798.1% | 73794.7% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 12779.7% | 167984.2% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 2837.2% | 38647.4% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | |
| Days sales outstanding | 461d | 11752d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 461d | 11752d | 0d | 0d | 0d | |
| Cash conversion cycle | 461d | 11752d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+81.3%EV / Sales ▼-82.5%EV / EBITDA ▼-125.9%EV / Op. cash flow ▼-2.585Earnings yield ▲+0.140
Profitability
Return on equity ▲+0.007Return on assets ▼-0.067Return on invested capital ▼-0.088Return on capital employed ▼-0.088Operating ROA ▲+0.001Income quality ▲+0.019Tax burden ▲+0.083
Efficiency
Days sales outstanding ▼-11291.396Days payables outstanding n/aOperating cycle ▼-11291.396Cash conversion cycle ▼-11291.396Capex / Sales ▼-371.260R&D / Sales ▼-1552.045
Balance-sheet strength
Current ratio ▼-1.801Net debt / EBITDA ▲+0.118Working capital ▼-109730000.000Invested capital ▼-100024000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-5.0%EV / Sales n/aEV / EBITDA ▲+69.6%EV / Op. cash flow ▲+9.064Earnings yield ▼-0.055
Profitability
Return on equity ▲+2.117Return on assets ▲+1.163Return on invested capital ▲+1.411Return on capital employed ▲+1.428Operating ROA ▲+1.509Income quality ▼-0.120Tax burden ▼-0.544
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+6.916Net debt / EBITDA ▲+0.361Working capital ▲+234980000.000Invested capital ▲+276848000.000Intangibles / Total assets ▼-0.011
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-14 ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK''s cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising ''going concern'' doubts.
- 2026-08-10 ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
- 2026-06-02 ProKidney Appoints Kenneth Locke as Chief Technical Officer Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel